Literature DB >> 3886935

Immunohistochemical studies of human renal cell carcinomas for ABO(H) blood group antigens, T antigen-like substance and carcinoembryonic antigen.

M Ghazizadeh, S Kagawa, K Kurokawa.   

Abstract

Immunohistochemical methods were used to examine human renal cell carcinoma tissues for the presence of ABO(H) blood group antigens, T antigen-like substance and carcinoembryonic antigen. None of the 30 tumors examined showed positive staining for the blood group antigens. In the normal adjacent kidney tissues blood group antigens were noted in the glomeruli, distal tubules and collecting ducts, while proximal convoluted tubules were uniformly negative. The presence of T antigen-like substance was noted in 10 of the 30 tumors (33 per cent). Likewise, T antigen-like substance appeared at the distal tubules and collecting ducts in the normal adjacent kidney tissues, while proximal convoluted tubules were negative. With a monoclonal antibody to carcinoembryonic antigen, 19 of the 30 tumors (63 per cent) showed positive staining. Carcinoembryonic antigen also was observed in the glomeruli and tubular epithelia in the normal kidney tissues. Immunohistochemical findings of T antigen-like substance and carcinoembryonic antigen were not found to be correlated with the tumor grade, cell type and stage, as well as survival of patients with renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886935     DOI: 10.1016/s0022-5347(17)49219-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  ABO blood group and risk of renal cell cancer.

Authors:  Hee-Kyung Joh; Eunyoung Cho; Toni K Choueiri
Journal:  Cancer Epidemiol       Date:  2012-07-26       Impact factor: 2.984

2.  Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features.

Authors:  Giovanna Giordano; Marzio Gabrielli; Letizia Gnetti; Teore Ferri
Journal:  World J Surg Oncol       Date:  2006-08-21       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.